Galcanezumab: Uses, Dosing, and Side Effects

Galcanezumab is a once-monthly injectable antibody designed to prevent migraine attacks by neutralizing a signaling molecule called calcitonin gene-related peptide, or CGRP, which plays a central role in triggering migraine pain. Sold under the brand name Emgality, it is approved for preventing both episodic and chronic migraine in adults and is the only CGRP antibody that also carries an approval for episodic cluster headache. The drug has been studied in several large trials, and the picture that emerges is one of meaningful headache reduction, a favorable safety profile, and a handful of common but mostly mild side effects worth knowing about before you start treatment.

How Galcanezumab Works

CGRP is a small protein released by nerve fibers around the brain’s blood vessels during a migraine attack. It dilates blood vessels, promotes inflammation, and amplifies pain signaling. Galcanezumab is a humanized monoclonal antibody that binds directly to the CGRP molecule itself, preventing it from latching onto its receptor and setting off that cascade.¹ Pharmacokinetic modeling shows that galcanezumab reduces free CGRP levels in a dose-dependent way, and the suppression is sustained with repeated monthly injections.²

This matters for understanding how galcanezumab differs from another CGRP antibody you may have heard of, erenumab (Aimovig). Erenumab blocks the CGRP receptor rather than the CGRP molecule. Because of that distinction, the two drugs affect slightly different signaling pathways in the brain. Functional imaging research has shown that galcanezumab specifically decreases activity in the hypothalamic area and brainstem regions, while erenumab acts more on the insula, thalamus, and cerebellum.³ Whether those differences translate into meaningfully different clinical outcomes for a given person is still being studied, but they do help explain why someone who does not respond to one class can sometimes benefit from switching to the other.

Approved Uses

Galcanezumab carries two distinct approvals. The first and most common use is the prevention of migraine in adults. This covers both episodic migraine (fewer than 15 headache days per month) and chronic migraine (15 or more). It is not a rescue medication you take during an attack; you inject it on a schedule to reduce how often attacks happen in the first place.

The second approval is for episodic cluster headache, a condition sometimes called “suicide headache” because the pain is so severe. In a randomized trial, patients receiving galcanezumab had their weekly cluster attacks drop by about 8.7 on average, compared with 5.2 in the placebo group, a difference of roughly 3.5 fewer attacks per week.⁴ Real-world data from patients with episodic cluster headache have been encouraging as well: about four in five patients achieved at least a 50 percent reduction in weekly attacks by the third week of treatment.⁵ Cluster headache has historically had very few preventive options, so this approval filled a significant gap.

How Well It Works for Migraine

Three pivotal Phase 3 trials form the backbone of the evidence for migraine prevention. In EVOLVE-1, which enrolled patients with episodic migraine, galcanezumab at 120 mg reduced monthly migraine days by 4.7, and the 240 mg dose reduced them by 4.6, compared with a 2.8-day reduction from placebo.⁶ EVOLVE-2, a similarly designed trial, found reductions of 4.3 and 4.2 days for the two doses versus 2.3 days for placebo.⁷

For chronic migraine, the REGAIN trial showed that galcanezumab 120 mg reduced monthly migraine days by 4.8 and the 240 mg dose by 4.6, compared with 2.7 days for placebo.⁸ In plain terms, if you had chronic migraine and were losing 19 or 20 days a month to headache, galcanezumab on average gave you back roughly two extra migraine-free days each month beyond what placebo did. That may sound modest on paper, but in quality-of-life terms those extra clear-headed days translate into real improvements in functioning and disability, as separate analyses of those trials confirmed.⁹

The CONQUER trial specifically enrolled patients who had already failed two to four prior preventive medications, the population most doctors would consider “treatment-resistant.” Even in this harder-to-treat group, galcanezumab produced significant improvements in migraine-specific quality-of-life scores and disability compared with placebo, and patients who crossed over from placebo during the open-label extension caught up to those who had received the drug from the start.¹⁰

Dosing and How to Take It

For migraine prevention, the standard regimen starts with a loading dose of 240 mg (given as two separate 120 mg injections) on the first day, followed by 120 mg once a month after that. The loading dose is meant to get blood levels up quickly. After a subcutaneous injection, galcanezumab reaches its peak concentration in about five days and has an elimination half-life of roughly 27 days, which is why once-monthly dosing works.¹¹

For episodic cluster headache, the dose is higher: 300 mg (three 100 mg injections) once a month, given at the start of and throughout a cluster period. You inject it under the skin of your abdomen, thigh, or upper arm. It comes as a prefilled pen or syringe that you can use at home.

Adherence tends to be better with galcanezumab than with older oral preventives such as topiramate, amitriptyline, or propranolol. A retrospective claims study found that patients on CGRP antibodies, and galcanezumab in particular, stuck with treatment longer and refilled more consistently than those on standard oral preventives.¹² That likely reflects both the simpler schedule and the fact that galcanezumab avoids many of the daily side effects (weight gain, brain fog, fatigue) that drive people off oral preventives. Long-term data from the open-label extension of the REGAIN chronic migraine trial also showed sustained efficacy and high adherence through 12 months of treatment.¹³

Common Side Effects

The most frequently reported side effect is a reaction at the injection site. In a pooled analysis of Phase 3 trials, about 18 to 23 percent of patients receiving galcanezumab reported at least one injection-site reaction, compared with roughly 13 percent on placebo.¹⁴ The most common was injection-site pain, which occurred at similar rates in the drug and placebo groups (about 10 to 12 percent versus 9.5 percent), suggesting some of it is simply from the needle. Redness, itching, and a nonspecific local reaction at the injection site were more clearly drug-related. The reassuring finding was that these reactions did not worsen over time with repeated dosing, and none led to serious adverse events.

Beyond the injection site, the side effects seen more often with galcanezumab than with placebo in integrated safety analyses included constipation, vertigo, and itching.¹⁵ These were generally mild to moderate and rarely led patients to stop treatment. Compared with the cognitive side effects commonly reported with topiramate or the weight gain associated with some older preventives, the side effect profile of galcanezumab is relatively clean.

Serious Reactions and Allergic Responses

Serious allergic reactions to galcanezumab are rare but documented. In one published case, a 50-year-old woman with a history of mast cell disorder developed injection-site swelling, facial redness, and flu-like symptoms the day after her first injection, progressing to lip and throat swelling the following day. She required intravenous steroids and antihistamines for her airway symptoms and recovered after a course of oral steroids.¹⁶ This patient had several preexisting immune conditions that likely increased her risk. The prescribing information for galcanezumab includes a warning about hypersensitivity reactions, and your prescriber may ask you to remain in the clinic for observation after your first injection if you have a history of severe allergies.

Because galcanezumab is a protein, the body can develop anti-drug antibodies against it. A review of immunogenicity data across all four CGRP monoclonal antibodies found that anti-drug antibody rates varied from less than 1 percent to about 18 percent, depending on the drug and the study. Neutralizing antibodies were less common, ranging from 0 to 12 percent.¹⁷ In galcanezumab-specific Phase 3 analyses, however, the presence of these antibodies did not reduce the drug’s blood levels or effectiveness, and there was no evidence that they drove injection-site reactions or hypersensitivity events.¹⁸

Cardiovascular Safety

CGRP has effects beyond pain signaling. It is also a potent vasodilator, which has raised theoretical concerns that blocking it might increase cardiovascular risk, especially in people who already have heart disease or elevated blood pressure. A dedicated analysis pooling cardiovascular outcomes across the three pivotal migraine trials found no meaningful signal. The rate of patients reporting at least one cardiovascular adverse event was about 2.6 percent with galcanezumab 120 mg and 3.3 percent with 240 mg, compared with 2.9 percent on placebo. Changes in blood pressure, heart rate, and heart rhythm were similar across all groups.¹⁹ The few serious cardiovascular events that did occur were split evenly between the drug and placebo groups and were not considered treatment-related.

That said, the clinical trials largely excluded patients with uncontrolled vascular disease, so the six-month safety window of the trials does not fully answer whether long-term CGRP blockade is safe in people with significant cardiovascular risk. Prescribers tend to be cautious when considering any CGRP antibody for patients with a recent stroke or heart attack.

Pregnancy and Breastfeeding

The honest answer here is that data are extremely thin. An analysis of the World Health Organization’s global safety reporting database identified 94 reports involving pregnancy exposure to any of the three CGRP antibodies (erenumab, galcanezumab, fremanezumab). About half of these involved drug exposure alone without any reported adverse outcome. Among those with adverse reactions, spontaneous miscarriage was the most commonly reported event, but the rate was not statistically higher than the background rate in the full database.²⁰

A case report of two women who continued galcanezumab into the first and second trimesters described normal deliveries and healthy newborns, with no apparent adverse effects during breastfeeding.²¹ Two cases are not enough to draw conclusions about safety, but they do add to the slowly accumulating human exposure data. Current guidance from most headache societies is to stop galcanezumab before a planned pregnancy and avoid it during breastfeeding unless the potential benefit justifies the unknown risk. Because of the drug’s long half-life (about 27 days), women trying to conceive are generally advised to wait at least five half-lives, roughly five months, after the last injection before becoming pregnant.

How Galcanezumab Compares to Other CGRP Antibodies

Four CGRP monoclonal antibodies are available: erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti, given by infusion). A head-to-head observational study comparing galcanezumab, fremanezumab, and erenumab found no significant differences in migraine day reduction or disability scores across the three drugs.²² A Bayesian network meta-analysis of chronic migraine trials suggested galcanezumab 120 mg and eptinezumab 300 mg might have a slight edge in reducing monthly migraine days, though fremanezumab showed the highest rate of patients achieving a 50 percent or greater response.²³ In practical terms, the four drugs are more alike than different, and the choice between them often comes down to insurance coverage, dosing preference (monthly injection versus quarterly injection versus infusion), and individual response.

An important nuance is that galcanezumab and fremanezumab both bind the CGRP molecule (they are “ligand” antibodies), while erenumab blocks the CGRP receptor. The two classes engage overlapping but not identical signaling pathways. Erenumab also antagonizes the amylin receptor, which galcanezumab does not.²⁴ This difference provides a rationale for switching between classes if the first drug does not work.

What Happens When Galcanezumab Does Not Work

Not everyone responds. Roughly a third to a half of patients treated with any single CGRP antibody do not achieve the commonly used benchmark of a 50 percent reduction in monthly migraine days. If galcanezumab has not produced a meaningful improvement after three to six months, your doctor has a few options.

One is switching to a different CGRP antibody. In a registry-based study of 21 patients who switched from galcanezumab to fremanezumab, about a third responded to the new drug, and the response rate was actually higher among those who had not responded to galcanezumab in the first place.²⁵ That small sample is not definitive, but it supports the idea that failure on one CGRP antibody does not rule out success with another, especially when switching between a ligand-targeting and a receptor-targeting drug.

Another strategy gaining traction is combining a CGRP antibody with onabotulinumtoxinA (Botox), which is separately approved for chronic migraine. A meta-analysis of six studies found that the combination reduced monthly headache days by about 7.9 days and cut acute medication use by about four days per month, with roughly half of patients reaching the 50 percent responder threshold.²⁶ The two drugs work through different mechanisms, which is presumably why combining them can help when either one alone falls short.

Insurance Coverage and Access

Cost is often the biggest practical barrier. Galcanezumab’s list price in the United States is several hundred dollars per month without insurance. The good news is that coverage has expanded significantly. An analysis of 149 U.S. insurance plans found that about 85 percent covered galcanezumab, though many required step therapy, meaning you have to try and fail one or more cheaper oral preventives before the insurer will approve a CGRP antibody.²⁷ These step therapy requirements remained largely in place even after the American Headache Society issued a 2024 consensus statement recommending more streamlined access to CGRP-targeted therapies. If your insurer denies coverage initially, your neurologist’s office can often file a prior authorization or appeal, and the manufacturer offers a savings program for commercially insured patients that can reduce out-of-pocket costs substantially.

The Role of CGRP in Non-Pain Functions

One area researchers continue to watch is whether long-term CGRP suppression has effects beyond headache. CGRP is not just a pain molecule. It helps regulate blood flow in the gut, protects against ischemic damage in the heart, and plays a role in wound healing. Blocking it chronically could, in theory, have subtle downstream consequences that would not show up in a six-month trial. So far, open-label extension studies running 12 months have not flagged new safety signals, and real-world experience now spans several years without alarming patterns emerging. But this remains an active area of surveillance, and it is one reason why some headache specialists prefer to re-evaluate the need for ongoing treatment periodically rather than leaving patients on galcanezumab indefinitely without reassessment.